Sight Sciences, Inc. – NASDAQ:SGHT
Founder-led company
Sight Sciences stock price today
$4.09
+0.52
+14.57%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Sight Sciences stock price monthly change
-53.09%
month
Sight Sciences stock price quarterly change
-53.09%
quarter
Sight Sciences stock price yearly change
-39.08%
year
Sight Sciences key metrics
Market Cap | 178.14M |
Enterprise value | 278.47M |
P/E | -5.14 |
EV/Sales | 2.69 |
EV/EBITDA | -2.21 |
Price/Sales | 4.15 |
Price/Book | 2.68 |
PEG ratio | -0.21 |
EPS | -1.12 |
Revenue | 81.49M |
EBITDA | -50.37M |
Income | -54.74M |
Revenue Q/Q | 2.34% |
Revenue Y/Y | 8.26% |
Profit margin | -128.91% |
Oper. margin | -124.72% |
Gross margin | 82.47% |
EBIT margin | -124.72% |
EBITDA margin | -61.81% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSight Sciences stock price history
Sight Sciences stock forecast
Sight Sciences financial statements
Average Price Target
$8.33
Potential upside: 103.74%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 23.47M | -14.75M | -62.86% |
|---|---|---|---|
| Sep 2023 | 20.00M | -13.03M | -65.15% |
| Dec 2023 | 18.75M | -10.69M | -57.02% |
| Mar 2024 | 19.26M | -16.26M | -84.43% |
| Jun 2023 | 185289000 | 49.15M | 26.53% |
|---|---|---|---|
| Sep 2023 | 176641000 | 49.57M | 28.06% |
| Dec 2023 | 166651000 | 46.43M | 27.86% |
| Mar 2024 | 155560000 | 46.35M | 29.8% |
| Jun 2023 | -13.48M | -97K | 766K |
|---|---|---|---|
| Sep 2023 | -9.82M | -304K | 118K |
| Dec 2023 | -6.48M | -264K | 376K |
| Mar 2024 | -9.78M | -117K | -942K |
Sight Sciences alternative data
| Aug 2023 | 250 |
|---|---|
| Sep 2023 | 250 |
| Oct 2023 | 250 |
| Nov 2023 | 250 |
| Dec 2023 | 250 |
| Jan 2024 | 250 |
| Feb 2024 | 250 |
| Mar 2024 | 214 |
| Apr 2024 | 214 |
| May 2024 | 214 |
| Jun 2024 | 214 |
| Jul 2024 | 214 |
Sight Sciences other data
49.58%
-3.84%
of SGHT is owned by hedge funds
23.65M
-1.75M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 29312 |
| Apr 2024 | 0 | 34129 |
| May 2024 | 0 | 13066 |
| Jul 2024 | 0 | 34774 |
| Oct 2024 | 0 | 118327 |
| Nov 2024 | 558426 | 551802 |
| Dec 2024 | 8376 | 0 |
| Patent |
|---|
Application Filling date: 27 May 2022 Issue date: 8 Sep 2022 |
Grant Utility: Ocular delivery systems and methods Filling date: 16 Dec 2021 Issue date: 19 Jul 2022 |
Grant Filling date: 15 May 2019 Issue date: 19 Jul 2022 |
Application Filling date: 16 Feb 2022 Issue date: 2 Jun 2022 |
Grant Utility: Ocular delivery systems and methods Filling date: 23 Apr 2021 Issue date: 31 May 2022 |
Application Filling date: 23 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 23 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 16 Dec 2021 Issue date: 7 Apr 2022 |
Application Filling date: 16 Dec 2021 Issue date: 7 Apr 2022 |
Grant Utility: Combination treatment systems Filling date: 9 Dec 2016 Issue date: 29 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 5 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 11 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Paul Badawi (1975) Co-Founder, Pres, Chief Executive Officer & Director | $496,710 |
Mr. Sam Boong Park (1961) Chief Operating Officer | $422,950 |
Mr. Shawn O'Neil (1973) Chief Commercial Officer | $413,930 |
-
What's the price of Sight Sciences stock today?
One share of Sight Sciences stock can currently be purchased for approximately $4.09.
-
When is Sight Sciences's next earnings date?
Unfortunately, Sight Sciences's (SGHT) next earnings date is currently unknown.
-
Does Sight Sciences pay dividends?
No, Sight Sciences does not pay dividends.
-
How much money does Sight Sciences make?
Sight Sciences has a market capitalization of 178.14M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.63% to 81.06M US dollars.
-
What is Sight Sciences's stock symbol?
Sight Sciences, Inc. is traded on the NASDAQ under the ticker symbol "SGHT".
-
What is Sight Sciences's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Sight Sciences?
Shares of Sight Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sight Sciences's key executives?
Sight Sciences's management team includes the following people:
- Mr. Paul Badawi Co-Founder, Pres, Chief Executive Officer & Director(age: 50, pay: $496,710)
- Mr. Sam Boong Park Chief Operating Officer(age: 64, pay: $422,950)
- Mr. Shawn O'Neil Chief Commercial Officer(age: 52, pay: $413,930)
-
Is Sight Sciences founder-led company?
Yes, Sight Sciences is a company led by its founder Mr. Paul Badawi.
-
How many employees does Sight Sciences have?
As Jul 2024, Sight Sciences employs 214 workers.
-
When Sight Sciences went public?
Sight Sciences, Inc. is publicly traded company for more then 4 years since IPO on 15 Jul 2021.
-
What is Sight Sciences's official website?
The official website for Sight Sciences is sightsciences.com.
-
Where are Sight Sciences's headquarters?
Sight Sciences is headquartered at 4040 Campbell Avenue, Menlo Park, CA.
-
How can i contact Sight Sciences?
Sight Sciences's mailing address is 4040 Campbell Avenue, Menlo Park, CA and company can be reached via phone at 877 266 1144.
-
What is Sight Sciences stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Sight Sciences in the last 12 months, the avarage price target is $8.33. The average price target represents a 103.74% change from the last price of $4.09.
Sight Sciences company profile:
Sight Sciences, Inc.
sightsciences.comExchange:
NASDAQ
Full time employees:
214
Industry:
Medical - Devices
Sector:
Healthcare
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
4040 Campbell Avenue
Menlo Park, CA 94025
Menlo Park, CA 94025
CIK: 0001531177
ISIN: US82657M1053
CUSIP: 82657M105
